CO2019005169A2 - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents

Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Info

Publication number
CO2019005169A2
CO2019005169A2 CONC2019/0005169A CO2019005169A CO2019005169A2 CO 2019005169 A2 CO2019005169 A2 CO 2019005169A2 CO 2019005169 A CO2019005169 A CO 2019005169A CO 2019005169 A2 CO2019005169 A2 CO 2019005169A2
Authority
CO
Colombia
Prior art keywords
polypeptide
seq
amino acid
set forth
nos
Prior art date
Application number
CONC2019/0005169A
Other languages
English (en)
Spanish (es)
Inventor
François Malouin
Céline Ster
Julie Côté-Gravel
Éric Brouillette
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of CO2019005169A2 publication Critical patent/CO2019005169A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CONC2019/0005169A 2016-10-21 2019-05-21 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus CO2019005169A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21
PCT/CA2017/051253 WO2018072031A1 (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections

Publications (1)

Publication Number Publication Date
CO2019005169A2 true CO2019005169A2 (es) 2019-08-09

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005169A CO2019005169A2 (es) 2016-10-21 2019-05-21 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Country Status (24)

Country Link
US (2) US11324815B2 (https=)
EP (1) EP3529260A4 (https=)
JP (2) JP7181208B2 (https=)
KR (1) KR20190082229A (https=)
CN (1) CN109843910A (https=)
AR (1) AR109847A1 (https=)
AU (2) AU2017346974B2 (https=)
BR (1) BR112019007796A2 (https=)
CA (1) CA3037070A1 (https=)
CL (1) CL2019001048A1 (https=)
CO (1) CO2019005169A2 (https=)
CR (1) CR20190249A (https=)
DO (1) DOP2019000102A (https=)
IL (1) IL265869A (https=)
MX (2) MX2019004539A (https=)
MY (1) MY195369A (https=)
NZ (1) NZ751880A (https=)
PE (1) PE20191320A1 (https=)
PH (1) PH12019500843A1 (https=)
RU (2) RU2766354C2 (https=)
SG (2) SG10201912431XA (https=)
TW (1) TW201819402A (https=)
UY (1) UY37448A (https=)
WO (1) WO2018072031A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777317A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
WO2022125928A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
WO2026014994A1 (ko) * 2024-07-12 2026-01-15 주식회사 더윤헬스텍 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE50983T1 (de) 1985-01-07 1990-03-15 Syntex Inc Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
EP2298341A3 (en) * 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
WO2006059846A1 (en) 2004-12-01 2006-06-08 Lg Life Sciences, Ltd. Formulation of sec1 mutated protein and method for formulation of the same
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
BRPI1011856A2 (pt) 2009-03-23 2020-11-03 Epitopix, Llc polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
LT2547361T (lt) 2010-03-17 2020-12-28 Socpra - Sciences Et Génie, S.E.C. Staphylococcus aureus bakterinės vakcinos komponentai ir jų naudojimas
NZ764564A (en) 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions

Also Published As

Publication number Publication date
EP3529260A1 (en) 2019-08-28
RU2019115303A (ru) 2020-11-23
RU2766354C2 (ru) 2022-03-15
US20190216913A1 (en) 2019-07-18
WO2018072031A1 (en) 2018-04-26
CL2019001048A1 (es) 2019-08-30
RU2022100889A (ru) 2022-04-06
EP3529260A4 (en) 2020-12-16
KR20190082229A (ko) 2019-07-09
BR112019007796A2 (pt) 2019-09-03
MY195369A (en) 2023-01-16
SG10201912431XA (en) 2020-02-27
JP2019531100A (ja) 2019-10-31
NZ751880A (en) 2023-04-28
AR109847A1 (es) 2019-01-30
CA3037070A1 (en) 2018-04-26
IL265869A (en) 2019-06-30
MX2019004539A (es) 2019-06-12
AU2022204585A1 (en) 2022-07-21
TW201819402A (zh) 2018-06-01
AU2017346974B2 (en) 2022-03-31
UY37448A (es) 2018-03-23
JP2023025066A (ja) 2023-02-21
DOP2019000102A (es) 2019-07-15
PH12019500843A1 (en) 2019-12-02
JP7181208B2 (ja) 2022-11-30
US20220288183A1 (en) 2022-09-15
PE20191320A1 (es) 2019-09-24
US11324815B2 (en) 2022-05-10
MX2023001219A (es) 2023-03-03
CN109843910A (zh) 2019-06-04
SG11201901483QA (en) 2019-03-28
RU2019115303A3 (https=) 2021-03-02
AU2017346974A1 (en) 2019-03-14
CR20190249A (es) 2019-10-16

Similar Documents

Publication Publication Date Title
CO2019005169A2 (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
MX2024002398A (es) Proteinas de fusion gdf15 y usos de estas.
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
CY1118029T1 (el) Βακτηριοφαγος ή λυτικη πρωτεϊνη που προερχεται απο το βακτηριοφαγο που ειναι αποτελεσματικα για την αντιμετωπιση βιομεμβρανης απο staphylococcus aureus
CY1118331T1 (el) Χιμαιρικα πολυπεπτιδια και η χρηση τους στην εκριζωση φορειας βακτηριων
AR083839A1 (es) Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
CO6731074A2 (es) Composición vacunal para el control de las infestaciones por ectoparásitos
CY1125681T1 (el) Εμβολια κατα του ιου της γριπης και χρησεις αυτων
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
AR065282A1 (es) Composiciones y metodos que utilizan arn de transferencia de genes tipo cad para el control de nematodos
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
AR060960A1 (es) Peptido, polinucleotico, secuencia celula transgenica, huesped viral, celula huesped, vector de expresion, uso y metodo de antagonistas de alta afinidad de quimioquinas elr- cxc
MX420767B (es) Proteina de union al factor h modificada
MX392412B (es) Polipéptidos que tienen actividad inductora de inmunidad.
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse
BR112022010228A2 (pt) Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
CL2017002972A1 (es) Péptido anti microbiano del tipo nk-lisina, para el control de agentes patógenos y su uso como adyuvante molecular.
AR133808A1 (es) Composiciones inmunogénicas contra la influenza
UY36802A (es) Vacuna contra la garrapata bovina conteniendo dos proteinas o peptidos derivados
AR117019A1 (es) Conjugados de interleuquina 10 y usos de los mismos